FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer
Titel:
FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer
Auteur:
Tamura, K. Shimizu, C. Hojo, T. Akashi-Tanaka, S. Kinoshita, T. Yonemori, K. Kouno, T. Katsumata, N. Ando, M. Aogi, K. Koizumi, F. Nishio, K. Fujiwara, Y.